Axis Wins, Avigilon Tripwire Patent Annulled
For approaching a decade, the fundamental Object Video tripwire patent has been at the core of an industry debate over patenting and video analytic usage. Now, that patent (acquired by Avigilon a few years ago) has been annulled as Axis / Canon's petition to invalidate the tripwire patent has been granted.
Inside this note, we examine the overall legal battle between Avigilon and Axis, how this was annulled and what impact it has for the industry.
Annulled ******
*** ********* ****** *** '***** ********' *** **** ******** ** **** *, **** ******** (*** ****** report), ************ *****:
*** ***** *** ********** ** **** a ******* ***** *********, ** ***** traffic ********** ****** **** **** ***** analytics ********* ********* *** ***********.
Central ******
**** **** ** ****,**** *********** ***** **** *****, *******, and ****, **** ********* ****** *** ** *** **** ** the **********. *** ****** ***** ** that *** ****** ** ** *********** to ****** *** ***** ******** ****** as ** ******* *********** (**** ********* and ******) ** **** ** ********* which *** ********* **** ** *********** specific ********* **** ****** ****** ** an ****** *****.
Ongoing **** / ******** ******
***** **** ** * *********** ***** in ******, **** ** **** ** a ****** ***** ****** ******* ******** and **** (*** **** ****** *****).** ****, ***** **** ******** *** patent ************. ***, **** ** *** **** 2 *****,**** ***** ** ********** * ******** patents, ********* **** *** **** *** Patent ***** **** ********. ** *** same ****, ******** **** **** *** violating ** ***.
*** ** **** *** **** * bit *********. *******,******** ******** ****** *****'* ******* ** 2014 *** $** *******, *********** ********** ***********'* ************* ****** ********* business ***** ********'* **** *** *** as * ***** ** ***** *******. Given *** ********* ** *** *******' validity (** *** ** ******* **** to ** ******* ******* *** *** frequently ********** ** * ******** ** Axis *** **** ****), **** ********** are ***** ****** **********.
Impact ** ******** ****** *********
********** **** *** ********** ** (** least) ******** ****, ********* **** ****** eliminates * ***** ******* *** ********* provider **** **** *** *** ********* Avigilon's *******. **** *** **** ********* a ******* *** **** ** **** a *** ****** ****** **** ** blocked / ****** ** * ***** competitor.
**** **** *** *** ********'* ****** licensing, ******, ** *** *****. ******** still *** **** ************ ** ***** ********* *******, ****** ******** *** ******** *** was *** **** ********.
****, ** ******* ** *** **** forever. *** ******** ****** *** **** *** 2000s **, ** **** ***** ** the **** *** *****, *** ****** would **** ****** ******* (****** **** we ****** ** ******* ***** ******* of ****** ***).
Adds ** ******* ************
**** ** *** ****** **** ** a **** **** **** *** *** a ****** ****-*** **** * **********. In ******** ****,******* ********* ************ ** ***** **** multi-imager ****** ***** *********** * ******* ****** ** ************ that ******.
Axis / ******** ******** *******
**** **** *** ******** ******** ** comment ** **** ** *** ******.
***** ********* *** ******** *** ******* ***** ********? I ***'* *** **. ******** ** no ****** * ******** ****** ******* as ** *** ******** ** ******** Solutions ***** ****** ** *** ****.
*** ******** ********* ** * ***** enough ******* **** * ******* ** businesses **** **** ** *********** **********. However, *** *** ***** ************ ********* market, ** ** ********.
***...***** ** *** :)))
******** **** *** ****** *** ****** on *** *****. ******* ****** **********.
******* ****** **********.
**** ***** *** ********. * *** you *** * ************. **** **** firm *** **** **** ******* ** play? **** ********* ****. **** * feel stifles ********** ** *** ******** ****** system ** **** ** *** **, the ******* **** ** ***** **, and *** ***** ****** ** ******* that **** ** ***** ********* *****. I'm *** ****** ******** *** ** abuser ** *** - * ****** don't ****. *********** *** ********** * patent ***** ** *** ***.
****: * *** *** **** *** disagree.
**** **** **** *** **** **** patents ** ****? **** ********* ****
**** ********* **** ******* *** **** defensively ****** **** ***********. **** *** the ***** **** **, **** ** became **** ******.
*** ** * ***'* ******** ***** with "******* ****** **********" *** * do ***** **'* **** ** *** that ****** ***** ******* ** ******* that *** ******* ******* ******* ****** considering ******** ***** *** *** * problem.
******* *** *** ****** **** ********** are ********* ** ********. *** *** come ** **** *** **** ***-**** thing. ** ***** **** ** *******, then *** ***** **** ******* *********** that **** *** *** **** ***-**** thing **** **** ****** **** ******* all **** ***** ****** *** **********. That's ** ************** ****, *** **** comment ** **** **************.
**
* *** ****, ** * *** product?
**'* * ****** ***** ********** **** I ******* ***** ***** ****** *********. It ** *********, *.*.,** **** ******** ********* ******.
* ** ******** ***** ** **** form ** ***** ****** ** ** so *** **'* ************* * **** of ********.
** **** ***, *** ** **** cost? ** *** ******* ****** ***, the ****** ** *** ** ****** soon. *** **** *** ***** ****** to ********** **** *** ******, *** much ******* *** **** **** ** have ** *** ** ******* ****? Would **** ****** **** ********** *** expensive ****** *****? ** * **** Avignon, * *** ***** ********* ***** after ****** *** ****** ** ****** Hill, "* **** ** ***** **** them ******* ** *** **** *****..."
***** **** ****** **** ********** *** expensive ****** *****?
*** ***** ** **** ** **** than **** * ****** ******. ******** now *** ** ** ********* ***** what **** ** ******* ** ** to ********'* ***** *******.
****, **** ** ****, **** **** more **** * ******* ******* ** revenue ** **** **** *** ***** where ** *** ** ***** ******** $100,000 ** ********** **** ****** ** save **** ** ****** *********.
**** **** **** *** **** ***** with ***** ****** ******* **** *** discussed ******* ** ********* ** ********/********? Does ***** **** *** ***** *** blood **** ******** *****'*? ****** ********, because **** *** ****** ***** ************.
*** ******** **** *** ******?